NASDAQ:IMVT | Free Cash Flow | Immunovant, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-03-31 to 2026-06-30
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-06-30-$124.41M
2026-03-31-$95.06M$8,000.00-$95.07M
2025-06-30-$117.41M$0.00-$117.41M
2025-03-31-$110.64M$201,000.00-$110.84M
2024-06-30-$76.2M$182,000.00-$76.38M
2024-03-31-$59.7M$150,000.00-$59.85M
2023-06-30-$47.37M$45,000.00-$47.42M
2023-03-31-$55.79M$26,000.00-$55.82M
2022-06-30-$65.82M$42,000.00-$65.86M
2022-03-31-$32.96M$118,000.00-$33.07M
2021-06-30-$21.21M$18,000.00-$21.23M
2021-03-31-$22.5M$95,000.00-$22.59M
2020-06-30-$13.8M$47,000.00-$13.85M
2020-03-31-$23.05M$10,000.00-$23.06M
2019-06-30-$8.33M$0.00-$8.33M
2019-03-31-$12.65M$0.00-$12.65M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$407.31M$8,000.00-$407.32M
2025-03-31-$375.87M$759,000.00-$376.63M
2024-03-31-$214.23M$360,000.00-$214.59M
2023-03-31-$188.19M$197,000.00-$188.39M
2022-03-31-$106.11M$254,000.00-$106.37M
2021-03-31-$83.33M$210,000.00-$83.54M
2020-03-31-$53.36M$31,000.00-$53.39M
2019-03-31-$28.55M$52,000.00-$28.6M